COX-2 Selectivity and Beyond: Exploring Polmacoxib Role in Knee Osteoarthritis Treatment

Knee osteoarthritis (KOA), a prevalent degenerative joint disease, significantly impacts global health, particularly among the elderly and individuals engaged in physically demanding jobs. Conventional treatments ranging from lifestyle modifications to NSAIDs and surgical interventions often provide limited long-term relief and may carry substantial risks, especially cardiovascular and gastrointestinal side effects. Polmacoxib, a novel NSAID and selective COX-2 inhibitor, offers a promising alternative due to its dual mechanism of action. It inhibits both COX-2 and carbonic anhydrase (CA), enabling tissue-specific action primarily in inflamed, CA-deficient joints. This dual inhibition not only helps reduce inflammation and pain but may also mitigate systemic side effects which are associated with traditional NSAIDs and COX-2 inhibitors. Pharmacokinetically, polmacoxib demonstrates a prolonged half-life and high erythrocyte binding, allowing sustained drug delivery to target tissues while minimizing plasma exposure. Clinical trials have shown that a once-daily dose of 2 mg polmacoxib is effective in reducing KOA symptoms, with efficacy comparable to celecoxib and a favourable safety profile. Studies also highlight its minimal cardiovascular and gastrointestinal risks, enhanced tolerability, and reduced need for additional protective medications. Approved in South Korea and India, polmacoxib has yet to receive FDA approval in the U.S. Nevertheless, it stands out as a potent, low-dose, and patient-compliant option for long-term KOA management. Further large-scale trials are essential to validate its long-term safety and potential disease-modifying effects, especially within diverse populations such as those in India.